Que faut-il retenir des recommandations de bonne pratique de la HAS 2022 : « Obésité de l’adulte : prise en charge de 2e et 3e niveaux – Partie I : prise en charge médicale » ?

IF 0.5 4区 医学 Q4 ENDOCRINOLOGY & METABOLISM
Judith Aron-Wisnewsky , Marie-Claude Brindisi
{"title":"Que faut-il retenir des recommandations de bonne pratique de la HAS 2022 : « Obésité de l’adulte : prise en charge de 2e et 3e niveaux – Partie I : prise en charge médicale » ?","authors":"Judith Aron-Wisnewsky ,&nbsp;Marie-Claude Brindisi","doi":"10.1016/S0985-0562(24)00012-8","DOIUrl":null,"url":null,"abstract":"<div><div>Presently in France, more than 8 million people are affected by obesity (17% of the French population), with an even higher prevalence among people from disadvantaged socio-economic backgrounds. This pathology requires a global, multi-professional, multimodal, adapted, and exhaustive management, taking into account all the associated comorbidities and the potential handicap caused by the severity of obesity. These best practice clinical recommendations, published in 2022, improves the management of patients with obesity through: (i) the development of a new clinical classification that graduates the severity of obesity beyond the sole BMI, allowing patients to be referred to the appropriate level of care; (ii) the exhaustive description of the evaluation content (medical, behavioral, psychological and social); (iii) the precision of the objectives and content of the needed therapeutic lifestyle modifications and (iv) the introduction and description of anti-obesity drug indications. These recommendations were then used by another working group to propose a guide for the care pathway of adults living with overweight and obesity (published in February 2023), and to broaden the indications for drug treatments for obesity (opinion on drugs, December 2022). Finally, these recommendations will be completed by a second part concerning the revision of the bariatric surgery recommendations (expected in 2024) in order to propose uniform and quality management of patients living with obesity.</div><div>© 2023 Société francophone nutrition clinique et métabolisme (SFNCM).</div><div>Published by Elsevier Masson SAS. All rights reserved.</div></div>","PeriodicalId":54702,"journal":{"name":"Nutrition Clinique et Metabolisme","volume":"37 2","pages":"Pages 2S52-2S57"},"PeriodicalIF":0.5000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nutrition Clinique et Metabolisme","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0985056224000128","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Presently in France, more than 8 million people are affected by obesity (17% of the French population), with an even higher prevalence among people from disadvantaged socio-economic backgrounds. This pathology requires a global, multi-professional, multimodal, adapted, and exhaustive management, taking into account all the associated comorbidities and the potential handicap caused by the severity of obesity. These best practice clinical recommendations, published in 2022, improves the management of patients with obesity through: (i) the development of a new clinical classification that graduates the severity of obesity beyond the sole BMI, allowing patients to be referred to the appropriate level of care; (ii) the exhaustive description of the evaluation content (medical, behavioral, psychological and social); (iii) the precision of the objectives and content of the needed therapeutic lifestyle modifications and (iv) the introduction and description of anti-obesity drug indications. These recommendations were then used by another working group to propose a guide for the care pathway of adults living with overweight and obesity (published in February 2023), and to broaden the indications for drug treatments for obesity (opinion on drugs, December 2022). Finally, these recommendations will be completed by a second part concerning the revision of the bariatric surgery recommendations (expected in 2024) in order to propose uniform and quality management of patients living with obesity.
© 2023 Société francophone nutrition clinique et métabolisme (SFNCM).
Published by Elsevier Masson SAS. All rights reserved.
求助全文
约1分钟内获得全文 求助全文
来源期刊
Nutrition Clinique et Metabolisme
Nutrition Clinique et Metabolisme 医学-内分泌学与代谢
CiteScore
0.80
自引率
16.70%
发文量
216
审稿时长
78 days
期刊介绍: Nutrition Clinique et Métabolisme is the journal of the French-speaking Society of Enteral and Parenteral Nutrition. Associating clinicians, biologists, pharmacists, and fundamentalists, the articles presented in the journal concern man and animals, and deal with organs and cells. The goal is a better understanding of the effects of artificial nutrition and human metabolism. Original articles, general reviews, update articles, technical notes and communications are published, as well as editorials and case reports.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信